Postovani profesore, posle dva gastroenterokolitisa u proteklih godinu dana verovatno virusnog porekla (trajanje istog dan dva) , javili su mi se crevni problemi, u vidu nadimanja, grceva creva, i neverovatnih vetrova neugodnog mirisa narocito posle podne do spavanja,posle rucka i vecere. Psaukj, paprike, voce,mlecni.proizvodi pogorsavaju stanje. Kolonoskopija radjena pre dve godine uredna. Radjene dve gastroskopije poslednja pre pola god,
uredna, a zbog pracenja blazeg gastritisa, uzimana terapija IPP duze vreme, dve godine. Osnovni nalazi krvi uredni, transaminaze uredne, uzv abdomena aerokolija, masna jetra, ostalo uredno. Slepo crevo izvadjeno pre tri godine, CRP i kalprotektin, uredni nalazi. Genetski nalaz na intoleranciju na laktozu uredan. Da vam ne govorim da sam stalno pod terapijom u
vidu probiotika, Flobiana, espumisana, nista ne pomaze. Medjutim nalaz koprokulture vec dva puta se vraca sa napomenom Candida spp. u velikom broju. Prvi put doktor kaze uredan nalaz to svako ima, ali zbog mojih tegoba drugi put propisuje ishranu bez belog hleba i secera i Nistatin tbl. 14 dana 3 x 2 tabl. Radio novi nalaz opet pise Candida spp 30%. Vetrovi neprijatnig mirisa, pretakanje po crevima i povremena naduvenost i dalje prisutni. Test na okultno krvarenje negativo. Sta da radim, moze savet molim vas? Moj doktor kaze Sindrom iritabilnog kolona,verovatno ali zasto Candida.
Verovatno jeste sindrom iritabilnog kolona, a probiotici su totalno suvišni, nema naučnh dokza da ičemu služe. candida albicans je normalni stanovnik creva i nije uzročnik bolesti, osim ezofagitisa, kod imunosuprimiranih- DIjeta koju pominjete nema nikakvog smisla. U prilogu je poglavlje iz udžbenika
Virus hepat. c van tela ostaje koliko ostaje. I ostaje i na celom pribora jeli tako.A metadon se sedmično jednom uzima u 6 bočica.Ako kupuješ od nekoga a taj neko verovatno ima HCV. Koja je verovatnoca , obratite pažnju, Da tome nekome spric nije bio sterilan pa je došao u kontakt sa metadonom a koji se opet pa nalazi u bočici- u bočici koju nije oprao tako da se nakon sedam dana ili manje "novi metadon " (koji spricem presipaju kad se deli terapija u bocice) u bocici zarazio i drugog nekog zarazio bez obzira na sterilan spric i iglu i alkohol?
Nekoliko godina borim se sa Enterobius vermicularisom. Svaki put dobijem isti lek -Soltrik 2 sirupa, da pijem jednom uveče. Kad popijem prvu bočicu za 2 nedelje da ponovim. Međutim kroz 3 meseca gliste se uvek vraćaju. Glavni simptom je svrab oko anusa, a radila sam i perianalni bris koji potvrđuje da imam gliste.
Ne znam šta da radim, ovaj Soltrik ne pomaže, ne znam da li su gliste postale otporne, kao ni da li može da naškodi mom organizmu ako ga često pijem....
Šta mi Vi preporučujete da uradim? Hvala unapred na odgovoru. Inače sam zdrava, nemam nikakve bolesti, nisam alergična ni na šta.
vi se očigledno iznova reinficirate. Neophodno je temeljno pranje veša, posteljine, na temperaturi ključana, a leče se i ostali ukućani, lekom izbora, mebendazol 1x 100mg, ili albendazol 1x400mg
Postovani, ogrebala me mačka lutalica juce po ruci. Krvarilo je. Danas sam otišla u kliniku i dali su mi tetanus vakcinu s obzirom da se ne secam kada sam zadnji put bila vakcinisana. Imam 35 god. Da li je to dovoljno? Na internetu sam pročitala da je potrebno dati i anti tetanus imunoglobin. Brinem se
multirezistentni S.aureus, najčešće je intrahospitalna infekcija, u zavisnosti od organa, ili tkiva koje je zahvaćeno, postoji lečenje.Evo u prilogu tekst iz udžbnika
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
For proven or suspected bloodstream infections,vancomycin or daptomycin
For pneumonia,vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Table
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
For proven or suspected bloodstream infections,vancomycin or daptomycin
For pneumonia,vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Table
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
For proven or suspected bloodstream infections,vancomycin or daptomycin
For pneumonia,vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Postovani profesore, posle dva gastroenterokolitisa u proteklih godinu dana verovatno virusnog porekla (trajanje istog dan dva) , javili su mi se crevni problemi, u vidu nadimanja, grceva creva, i neverovatnih vetrova neugodnog mirisa narocito posle podne do spavanja,posle rucka i vecere. Psaukj, paprike, voce,mlecni.proizvodi pogorsavaju stanje. Kolonoskopija radjena pre dve godine uredna. Radjene dve gastroskopije poslednja pre pola god, uredna, a zbog pracenja blazeg gastritisa, uzimana terapija IPP duze vreme, dve godine. Osnovni nalazi krvi uredni, transaminaze uredne, uzv abdomena aerokolija, masna jetra, ostalo uredno. Slepo crevo izvadjeno pre tri godine, CRP i kalprotektin, uredni nalazi. Genetski nalaz na intoleranciju na laktozu uredan. Da vam ne govorim da sam stalno pod terapijom u vidu probiotika, Flobiana, espumisana, nista ne pomaze. Medjutim nalaz koprokulture vec dva puta se vraca sa napomenom Candida spp. u velikom broju. Prvi put doktor kaze uredan nalaz to svako ima, ali zbog mojih tegoba drugi put propisuje ishranu bez belog hleba i secera i Nistatin tbl. 14 dana 3 x 2 tabl. Radio novi nalaz opet pise Candida spp 30%. Vetrovi neprijatnig mirisa, pretakanje po crevima i povremena naduvenost i dalje prisutni. Test na okultno krvarenje negativo. Sta da radim, moze savet molim vas? Moj doktor kaze Sindrom iritabilnog kolona,verovatno ali zasto Candida.
Odgovoreno: 29. 09. 2022.Verovatno jeste sindrom iritabilnog kolona, a probiotici su totalno suvišni, nema naučnh dokza da ičemu služe. candida albicans je normalni stanovnik creva i nije uzročnik bolesti, osim ezofagitisa, kod imunosuprimiranih- DIjeta koju pominjete nema nikakvog smisla. U prilogu je poglavlje iz udžbenika
Virus hepat. c van tela ostaje koliko ostaje. I ostaje i na celom pribora jeli tako.A metadon se sedmično jednom uzima u 6 bočica.Ako kupuješ od nekoga a taj neko verovatno ima HCV. Koja je verovatnoca , obratite pažnju, Da tome nekome spric nije bio sterilan pa je došao u kontakt sa metadonom a koji se opet pa nalazi u bočici- u bočici koju nije oprao tako da se nakon sedam dana ili manje "novi metadon " (koji spricem presipaju kad se deli terapija u bocice) u bocici zarazio i drugog nekog zarazio bez obzira na sterilan spric i iglu i alkohol?
Odgovoreno: 27. 09. 2022.verovatnoća postoji, ali je ipak rizik mali.
Poštovani, imam 23 godine.
Nekoliko godina borim se sa Enterobius vermicularisom. Svaki put dobijem isti lek -Soltrik 2 sirupa, da pijem jednom uveče. Kad popijem prvu bočicu za 2 nedelje da ponovim. Međutim kroz 3 meseca gliste se uvek vraćaju. Glavni simptom je svrab oko anusa, a radila sam i perianalni bris koji potvrđuje da imam gliste.
Ne znam šta da radim, ovaj Soltrik ne pomaže, ne znam da li su gliste postale otporne, kao ni da li može da naškodi mom organizmu ako ga često pijem....
Šta mi Vi preporučujete da uradim? Hvala unapred na odgovoru. Inače sam zdrava, nemam nikakve bolesti, nisam alergična ni na šta.
Pozdrav
Odgovoreno: 27. 09. 2022.vi se očigledno iznova reinficirate. Neophodno je temeljno pranje veša, posteljine, na temperaturi ključana, a leče se i ostali ukućani, lekom izbora, mebendazol 1x 100mg, ili albendazol 1x400mg
Postovani, ogrebala me mačka lutalica juce po ruci. Krvarilo je. Danas sam otišla u kliniku i dali su mi tetanus vakcinu s obzirom da se ne secam kada sam zadnji put bila vakcinisana. Imam 35 god. Da li je to dovoljno? Na internetu sam pročitala da je potrebno dati i anti tetanus imunoglobin. Brinem se
Odgovoreno: 27. 09. 2022.dovoljna je vakcina, a imuglobulin se daje nevakcinisanim, a vi ste kao dete vakcinisani i naravno da se ne sećate
Postovani molim vas da mi odgovorite....Zanima me sve o bakteriji MRSA PVL ..kome da se obratim i da li je uopste izleciva...Hvala
Odgovoreno: 27. 09. 2022.multirezistentni S.aureus, najčešće je intrahospitalna infekcija, u zavisnosti od organa, ili tkiva koje je zahvaćeno, postoji lečenje.Evo u prilogu tekst iz udžbnika
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
For proven or suspected bloodstream infections, vancomycin or daptomycin
For pneumonia, vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Table
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
For proven or suspected bloodstream infections, vancomycin or daptomycin
For pneumonia, vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Table
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
For proven or suspected bloodstream infections, vancomycin or daptomycin
For pneumonia, vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Prikazano 1936-1940 od ukupno 5241 pitanja
Pregledajte odgovore po oblastima
Prijavite se
Dobro došli! Unesite svoje login podatke